Lithium-associated primary hyperparathyroidism complicated by nephrogenic diabetes insipidus
- PMID: 26504422
- PMCID: PMC4605114
- DOI: 10.5152/UCD.2014.2859
Lithium-associated primary hyperparathyroidism complicated by nephrogenic diabetes insipidus
Abstract
Lithium-associated hyperparathyroidism is the leading cause of hypercalcemia in lithium-treated patients. Lithium may lead to exacerbation of pre-existing primary hyperparathyroidism or cause an increased set-point of calcium for parathyroid hormone suppression, leading to parathyroid hyperplasia. Lithium may cause renal tubular concentration defects directly by the development of nephrogenic diabetes insipidus or indirectly by the effects of hypercalcemia. In this study, we present a female patient on long-term lithium treatment who was evaluated for hypercalcemia. Preoperative imaging studies indicated parathyroid adenoma and multinodular goiter. Parathyroidectomy and thyroidectomy were planned. During the postoperative course, prolonged intubation was necessary because of agitation and delirium. During this period, polyuria, severe dehydration, and hypernatremia developed, which responded to controlled hypotonic fluid infusions and was unresponsive to parenteral desmopressin. A diagnosis of nephrogenic diabetes insipidus was apparent. A parathyroid adenoma and multifocal papillary thyroid cancer were detected on histopathological examination. It was thought that nephrogenic diabetes insipidus was masked by hypercalcemia preoperatively. A patient on lithium treatment should be carefully followed up during or after surgery to prevent life-threatening complications of previously unrecognized nephrogenic diabetes insipidus, and the possibility of renal concentrating defects on long-term lithium use should be sought, particularly in patients with impaired consciousness.
Keywords: Lithium; hyperparathyroidism; nephrogenic diabetes insipidus.
Figures
References
-
- Vestergaard P, Licht RW. 50 years with lithium treatment in affective disorders. World J Biol Psychiatry. 2001;2:18–26. http://dx.doi.org/10.3109/15622970109039980. - DOI - PubMed
-
- Lazarus JH. Lithium and thyroid. Best Pract Res Clin Endocrinol Metab. 2009;23:723–733. http://dx.doi.org/10.1016/j.beem.2009.06.002. - DOI - PubMed
-
- Bedford JJ, Weggery S, Ellis G, MacDonald FJ, Joyce PR, Leader JP, et al. Lithium induced nephrogenic diabetes insipidus: renal effects of amiloride. Clin J Am Soc Nephrol. 2008;3:1324–1331. http://dx.doi.org/10.2215/CJN.01640408. - DOI - PMC - PubMed
-
- Wang W, Li C, Kwon TH, Knepper MA, Frokiaer J, Nielsen S. AQP3, p-AQP2 and AQP2 expression is reduced in polyuric rats with hypercalcemia. Prevention by cAMP-PDE inhibitors. Am J Physiol Renal Physiol. 2002;283:1313–1325. http://dx.doi.org/10.1152/ajpcell.00553.2001. - DOI - PubMed
-
- Szalat A, Mazeh H, Freund HR. Lithium-associated hyperparathyroidism: report of four cases. Eur J Endocrinol. 2009;160:317–323. http://dx.doi.org/10.1530/EJE-08-0620. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources